Information Letter No. 10

It is a great pleasure to present you the 10th Information Letter of the ELN. Topics of the current issue range from basic research to diagnostics all the way to leukemia therapy. It also contains the latest news from the ELN Foundation and EUTOS, about current trials in the European Leukemia Trial Registry, and summaries of the most important clinical results from oral presentations of the 55. ASH Annual Meeting and Exposition which were selected and precised by ELN experts. ▶ Information Letter online

MDS Pocket Card

Based on the recent publication of the European LeukemiaNet recommendations for the diagnosis and treatment of primary myelodysplastic syndromes in adults, the ELN developed a MDS pocket card. Ordering information and the pocket card in PDF format are now available on the website. ▶ MDS pocket card

This is what the ELN looks like

For more than ten years now, scores of international experts have gathered in Mannheim in February for the Annual Symposium of the European LeukemiaNet. A group picture of this year's participants is now available online. ▶ Group picture

Publications from the Network (selected)

Acute lymphoblastic leukemia


Acute myeloid leukemia

- Willemze R et al. High-Dose Cytarabine in Induction Treatment Improves the Outcome of Adult Patients Younger Than Age 46 Years With Acute Myeloid Leukemia: Results of the EORTC-GIMEMA AML-12 Trial. J
Chronic myeloid leukemia  

Chronic lymphocytic leukemia  

Myelodysplastic syndromes  
- de Witte T. Iron chelators in myelodysplastic syndrome: to lower ferritin levels or to improve survival? Leuk Res. 2013 Dec;37(12):1605.

Myeloproliferative neoplasms  

Stem cell transplantation  

Miscellaneous


New trials in the ELTR

**EXPAND** Study of the JAK Inhibitor Ruxolitinib administered orally to patients with Primary Myelofibrosis (PMF), Post-Polycythemia Vera-Myelofibrosis (PPV-MF) or Post-Essential Thrombocythemia-Myelofibrosis (PET-MF)(CINC424A2201)

**CLBH589X2106** A Phase 1b, Open-label, Multi-center, Single Arm, Dose Finding Study to Assess Safety and Pharmacokinetics of the Oral Combination of Panobinostat and Ruxolitinib in Patients With Primary Myelofibrosis (PMF), Post-polycythemia Vera-myelofibrosis (PPV-MF) or Post-essential Thrombocythemia-myelofibrosis (PET-MF)